3B BlackBio Dx Ltd. has announced a scheduled analyst/investor meeting with Fair Value Capital as part of its regulatory compliance under SEBI guidelines. The virtual interaction is planned for March 17, 2026, representing the company's ongoing engagement with institutional investors.

Meeting Details and Schedule

The company has formally notified BSE Limited about the upcoming analyst meeting through a regulatory filing dated March 12, 2026. The structured interaction will provide Fair Value Capital with insights into the company's business operations and financial performance.

Regulatory Compliance Framework

The meeting is being conducted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has emphasized its commitment to maintaining transparency while adhering to regulatory guidelines for investor interactions.

Key compliance aspects include:

• Use of Q3-FY26 investor presentation previously shared with stock exchange
• Restriction to publicly available information only
• No sharing of unpublished price sensitive information
• Formal notification to BSE Limited

Presentation and Information Sharing

3B BlackBio Dx Ltd. will utilize its Q3-FY26 investor presentation during the meeting, which was earlier communicated to the stock exchange through reference number P-66/2025-26/74 dated February 6, 2025. The company has clearly stated that discussions will be limited to information available in the public domain.

The meeting details have been made available on the company's website at www.Kilpest.com , ensuring transparency and accessibility for all stakeholders. The company has noted that the scheduled date and time may be subject to change due to exigencies on either party's part.

Corporate Communication

The formal communication was signed by Nikhil Kuber Dubey, Whole Time Director (DIN: 00538049), and digitally authenticated on March 12, 2026. This represents the company's systematic approach to investor relations and regulatory compliance as 3B BlackBio Dx Limited, formerly known as Kilpest India Limited.

3b blackbio dx Limited has released the transcript of its Q3 FY26 earnings conference call held on February 21, 2026, providing comprehensive insights into the company's financial performance and strategic initiatives following its successful participation at MEDLAB Dubai.

Strong Financial Performance with Coris Integration

The company reported robust nine-month revenue growth, with consolidated figures reaching INR99.06 crores compared to INR64.80 crores in the previous year. The standalone 3B business demonstrated solid growth of 11.8%, which would have been over 20% excluding seasonal fluctuations from dengue and flu outbreaks.

Coris Acquisition Performance and HAT Contract

The Belgium-based Coris acquisition contributed INR24 crores in quarterly revenue, including INR8.8 crores from the one-off HAT (Human African Trypanosomiasis) contract. This contract, originally valued at USD6 million over four years, is expected to continue generating approximately USD1.5 million annually for the next two years.

Market Position and Competitive Landscape

Chairman and Managing Director Dhirendra Dubey highlighted the company's strong market position, commanding 12-15% market share in India's molecular diagnostics reagent market, valued at approximately INR400-500 crores. The company exports to 70 countries, with TRUPCR Europe showing 20%+ growth driven by "Made in UK" credibility.

Strategic Initiatives and Product Development

The company is advancing several strategic initiatives including sample-to-answer machine development through OEM partnerships, automated extraction systems, and highly multiplexed panels for respiratory and AMR testing. The European IVDR certification process is underway for 35-40 key products, representing over 95% of European revenue.

Growth Outlook and Financial Guidance

Management provided guidance for 10-15% overall growth and 15-20% export growth for the current year. The company maintains a cash position of approximately INR190 crores post-Coris acquisition, with INR130-140 crores earmarked for future acquisitions. Two consultants have been appointed to identify acquisition opportunities.

Regulatory and Market Expansion

Coris has initiated US FDA registration processes, expected to complete within 1-2 years, opening access to the substantial US market. The company plans to participate in ADLM USA, showcasing products from all three entities: 3B, TRUPCR Europe, and Coris, targeting Latin American and US distributors.